Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$0.51.

  • InMed Pharmaceuticals' EPS (Basic) rose 8598.9% to -$0.51 in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.32, marking a year-over-year increase of 7557.03%. This contributed to the annual value of -$8.36 for FY2025, which is 5847.58% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.51 for Q4 2025, which was up 8598.9% from -$0.44 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' EPS (Basic) ranged from a high of -$0.14 in Q2 2023 and a low of -$15.24 during Q3 2023
  • In the last 5 years, InMed Pharmaceuticals' EPS (Basic) had a median value of -$3.61 in 2024 and averaged -$4.22.
  • Per our database at Business Quant, InMed Pharmaceuticals' EPS (Basic) surged by 9894.58% in 2023 and then crashed by 256238.74% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' EPS (Basic) stood at -$7.73 in 2021, then soared by 88.23% to -$0.91 in 2022, then crashed by 307.69% to -$3.71 in 2023, then grew by 1.89% to -$3.64 in 2024, then surged by 85.99% to -$0.51 in 2025.
  • Its last three reported values are -$0.51 in Q4 2025, -$0.44 for Q3 2025, and -$1.83 during Q2 2025.